AnthonyT., BaronT., MercadanteS.Report of the clinical protocol committee: development of randomized trials for malignant bowel obstruction.J Pain Symptom Manage2007; 34(1 Suppl): S49–S59.
2.
FeuerD.J., BroadleyK.E., ShepherdJ.H.Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer.Cochrane Database Syst Rev2000; 4: CD002764.
3.
FainsingerR., SpachynskiK., HansonJ.Symptom control in terminally ill patients with malignant bowel obstruction (MBO).J Pain Symptom Manage1994; 9(1): 12–18.
4.
KucukmetinA., NaikR., GalaalK.Palliative surgery versus medical management for bowel obstruction in ovarian cancer.Cochrane Database Syst Rev2010; 7: CD007792. doi: 10.1002/14651858. CD007792.pub2.
5.
DolanE.A.Malignant bowel obstruction: a review of current treatment strategies.Am J Hosp Palliat Care2011; 28(8): 576–582. doi: 10.1177/1049909111406706.
Paul OlsonT.J., PinkertonC., BraselK.J.Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review.JAMA Surg2014; 149(4): 383–392. doi: 10.1001/jamasurg.2013.4059.
8.
SugarbakerP.H.Successful management of microscopic residual disease in large bowel cancer.Cancer Chemother Pharmacol1999; 43(Suppl): S15–S25.
9.
KobayashiH., EnomotoM., HiguchiT.Validation and clinical use of the Japanese classification of colorectal carcino-matosis: benefit of surgical cytoreduction even without hyper-thermic intraperitoneal chemotherapy.Dig Surg2010; 27(6): 473–480. doi: 10.1159/000320460.
10.
GillyF.N., CarryP.Y., SayagA.C.Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis.Hepatogastro-enterology1994; 41(2): 124–129.
11.
MularskiR.A., RosenfeldK., CoonsS.J.Measuring outcomes in randomized prospective trials in palliative care.J Pain Symptom Manage2007; 34(1 Suppl): S7–S19.
12.
RipamontiC., TwycrossR., BainesM.Clinical-practice recommendations for the management of bowel obstruction in patients with end-stage cancer.Support Care Cancer2001; 9(4): 223–233.
13.
GoldsteinN.E., MorrisonR.S.Evidence-based practice of palliative medicine.Philadelphia: Elsevier Saunders; 2013.
14.
AlbibiR., McCallumR.W.Metoclopramide: pharmacology and clinical application.Ann Intern Med1983; 98(1): 86–95.
15.
SmithR.Safety of ondansetron.Eur J Cancer Clin Oncol1989; 25(1 Suppl): S47–S50; discussion S51–S54.
16.
MercadanteS., PorzioG.Octreotide for malignant bowel obstruction: twenty years after.Criti Rev Oncol Hematol2012; 83(3): 388–392. doi: 10.1016/j.critrevonc.2011.12.006.
17.
MystakidouK., TsilikaE., KalaidopoulouO.Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double-blind, controlled clinical trial.Anticancer Res2002; 22(2B): 1187–1192.
18.
MercadanteS.Comparison of octreotide and hyoscine butyl-bromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.Support Care Cancer2000; 8(3): 188–191.
19.
RipamontiC.Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.J Pain Symptom Manage2000; 19(1): 23–34.
20.
LavalG., RousselotH., Toussaint-MartelS.SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction.Bull Cancer2012; 99(2): E1–E9. doi: 10.1684/bdc.2011.1535.
21.
MarianiP., BlumbergJ., LandauA.Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study.J Clin Oncol2012; 30(35): 4337–4343. doi: 10.1200/JCO.2011.40.5712.
22.
CurrowD.C., QuinnS., AgarM.Double-blind, placebo-controlled, randomised trial of octreotide in malignant bowel obstruction.J Pain Symptom Manage. Forthcoming.
23.
FeuerD., BroadleyK., Systematic Review Steering Committee. Systematic review and meta-analysis of corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancers.Ann Oncol1999; 10(9): 1035–1041. doi: 10.1023/A:1008361102808.
24.
BuchmanA.Side effects of corticosteroid therapy.J Clin Gas-troenterol2001; 33(4): 289–294.
25.
ClarkK., LamL., CurrowD.Reducing gastric secretions — a role for histamine 2 antagonists or proton pump inhibitors in malignant bowel obstruction?Support Care Cancer2009; 17(12): 1463–1468. doi: 10.1007/s00520-009-0609-3.
26.
LavalG., Marcelin-BenazechB., GuirimandF.Recommendations for bowel obstruction with peritoneal carcinomatosis.J Pain Symptom Manage2014; 48(1): 75–91. doi: 10.1016/j.jpainsymman.2013.08.022.
27.
KrouseR.S.The international conference on malignant bowel obstruction: a meeting of the minds to advance palliative care research.J Pain Symptom Manage2007; 34(1 Suppl): S1–S6.
28.
Shelby-JamesT., HardyJ., AgarM.Designing and conducting randomized controlled trials in palliative care: a summary of discussions from the 2010 clinical research forum of the Australian Palliative Care Clinical Studies Collaborative.Palliat Med2012; 26(8): 1042–1047. doi: 10.177/0269216311417036.
29.
AbernethyA., AzizN., BaschE.A strategy to advance the evidence base in palliative medicine: formation of a palliative care research cooperative group.J Palliat Med2010; 13(12): 1407–1413. doi: 10.089/jpm.2010.0261.
30.
LeblancT.W., KutnerJ.S., KoD.Developing the evidence base for palliative care: formation of the Palliative Care Research Cooperative and its first trial.Hosp Pract (1995)2010; 38(5): 137–143. doi: 10.3810/hp.2010.06.320.
31.
GroenvoldM., PetersenM.A., AaronsonN.K.The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care.Eur J Cancer2006; 42(1): 55–64.
32.
CellaD.F., TulskyD.S., GrayG.The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.J Clin Oncol1993; 11(3): 570–579.
33.
SteinhauserK.E., VoilsC.I., ClippE.C.“Are you at peace?”: one item to probe spiritual concerns at the end of life.Arch Intern Med2006; 166(1): 101–105.
34.
BiagiC., MontanaroN., BuccellatoE.Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).Eur J Clin Pharmacol2013; 69(2): 237–244. doi: 10.1007/s00228-012-1321-7.
35.
CurrowD., RowettD., DoogueM.An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice.J Palliat Med2012; 15(3): 282–286. doi: 10.1089/jpm.2012.9605.
